Forum Topic News
  • Conversation: Uni-Bio Science's Anti-diabetic Acarbose Oral Tablets BE Study Application Accepted by the National Medical Products Administration

    • January 6, 2019 8:23 PM GMT
    • Uni-Bio Science's Anti-diabetic Acarbose Oral Tablets BE Study Application Accepted by the National Medical Products Administrat...

      A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited , together with its subsidiaries, is pleased to announce that the bioequivalence study ("BE Study") and its clinical materials on Acarbose tablets jointly developed by Beijing Genetech Pharmaceutical Co., Limited (a wholly-owned subsidiary of the Company) and Beijing Baiao Pharmaceutical Co., Ltd. has been formally accepted by the National Medical Products Administration ("NMPA") with reference number of CYHS1900008GUO and CYHS1900007GUO, corresponding to the oral tablets under two specifications of 50mg and 100mg for this submission respectively. This submission, if approved, means that the Company will be qualified for batch production of such product, which will be produced and launched to the Mainland China market as newly approved generic drugs.
      Acarbose tablet is an oral anti-diabetic drug which belongs to the Alpha-Glucosidase Inhibitors class. It is used to treat Type 2 diabetes and is reimbursed under the National Reimbursement Drug List. It targets patients with pre-diabetes condition who need to be treated in early stage, and those with post prandial hyperglycemia under control.
      Read more: https://www.prnewswire.com/news-releases/uni-bio-sciences-anti-diabetic-acarbose-oral-tablets-be-study-application-accepted-by-the-national-medical-products-administration-300773017.html

Add Reputation

Do you want to add reputation for this member by this post?

or cancel